[ad_1] This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim in eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial…
[ad_1] Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market…
[ad_1] An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right…
[ad_1] Monty Rakusen | Digitalvision | Getty Images If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don’t need to look much further than weight loss drugs. On the human side, Novo Nordisk and Eli Lilly struggled to meet the demand for Ozempic, Wegovy, Mounjaro…
[ad_1] Image of a healthy liver not ravaged by fatty liver disease. BSIP | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drugmakers aren’t just racing to develop drugs that treat obesity. They’re also competing to expand the uses of those weight loss treatments,…
[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank of America analyst Geoff Meacham has been very bullish about the opportunity, which he calls “unprecedented” given the prevalence of obesity and the huge…
[ad_1] The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman…
[ad_1] Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used…
[ad_1] It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end,…
